anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides improved methods and products based on adenoviral materials which can advantageously be used in for instance gene therapy. In one aspect an adenoviral vector is provided which has no overlap with a suitable packaging cell line which is another aspect of invention. This combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. In another aspect an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Further a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, which all have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system. Further a method of intracellular amplification is provided.
The present invention provides a vascular bracket covered with arsenic oxide films and a preparation method thereof, which relates to a medicine coating bracket and a preparation method thereof. The existing vascular bracket has the problems of insufficient tightness of the medicine coating and the bracket, easy film falling and poor elasticity. The vascular bracket covered with arsenic oxide films is characterized in that the medicine coating is only an oxide film layer of arsenic. The preparation method of the vascular bracket covered with arsenic oxide films orderly comprises the steps that an arsenic film is generated on a support frame via molecular beam epitaxy, and the support frame after coated by the film is arranged in the air for natural oxidation. Another preparation method orderly comprises the steps that arsenic is plated on the surface of the support frame by an evaporation film coating method, and the support frame after coated by the film is arranged in the air for natural oxidation. The film of the present invention has the advantages of hard falling and good elasticity, and the preparation method of the present invention is simple and practical and is favorable to popularization and application.
Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
UNLABELLED: Brief rationale: Zoledronic acid treatment against osteoporosis is limited by APR. Main result: Combination therapy (hydrocortisone plus non-steroidal anti-inflammatory drugs, acetaminophen, and prednisolone) reduced intolerable APR levels and provided complete symptom relief in most patients. Significance of the paper: Combination therapy can enhance patient outcomes in osteoporosis management.
PURPOSE: Osteoporosis is a common condition associated with high morbidity rates, often requiring treatment with bisphosphonates such as zoledronic acid. However, the persistence to zoledronic acid infusion is commonly limited by acute phase response (APR). This retrospective study aimed to evaluate the efficacy of a novel combination therapy in preventing APR symptoms.
METHODS: A retrospective case-control study was conducted on 931 patients who received their first zoledronic acid infusion between 2011 and 2021. We evaluated the efficacy of combination therapy comprising a single dose of hydrocortisone prior to the infusion and a 3-d oral regimen of non-steroidal anti-inflammatory drugs, acetaminophen, and prednisolone following the infusion. Patients were divided into protocol (receiving combination therapy) and control groups (without treatment). Baseline characteristics, APR incidence, and the efficacy of symptom control were compared between groups using Fisher's exact test and Student's t-test.
RESULTS: There was no difference in APR incidence between the protocol (n = 507) and control group (n = 407; p = 0.1442). However, the protocol group exhibited lower intolerable APR levels (3.72% vs. 16.71%; p < 0.0001) and complete symptom relief in 96.28% of cases.
CONCLUSION: The combination therapy protocol effectively reduced intolerable APR and relieved symptoms in most patients following zoledronic acid infusion. This study highlights the importance of proactive management strategies for APR and emphasizes the potential of combination therapy in alleviating APR symptoms and reducing the occurrence of severe APR in patients undergoing osteoporosis management.
It is considered that the disruption of the function of Rap1 as an integrin adhesion regulatory molecule would closely relate to the pathological conditions of immune diseases such as inflammation, allergy, autoimmune disease, cancer immunity and transplantation immunity. Thus, it is expected that the clarification of the integrin adhesion regulatory mechanism by Rap1 contributes to the understanding of the pathological conditions of these immune diseases and the development of therapies therefor. p30 is identified as a molecule relating to the integrin adhesion regulation by Rap1. It is found out that p30 binds to Rap1 and thus controls its function. Use of this finding makes it possible to develop an inhibitor of the binding of p30 to Rap1, develop remedies for inflammation, allergy, autoimmune disease, cancer immunity, transplantation immunity, etc. and, in its turn, clarify the regulatory mechanism.
The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
The invention relates to a traditional Chinese medical ointment for treating shoulder-hand syndrome as well as a preparation method thereof. The problem of medicines for treating shoulder-hand syndrome can be effectively solved. The traditional Chinese medical ointment shoulder-hand syndrome is prepared from the following raw materials by weight: 5-15g of Angelica sinensis, 5-15g of Ligusticum wallichii, 12-20g of root of common peony, 7-15g of monkshood, 5-18g of radix aconiti carmichaeli, 7-20g of cassia twig, 6-18g of pepper, 5-12g of radix sileris, 5-18g of the root of red-rooted salvia, 8-18g of radix angelicae pubescentis, 6-18g of notopterygium root, 5-15g of cynanchum paniculatum, 1-3g of asarum and 90-110g of emulsifiable paste matrix. With the adoption of the supercritical extraction technology and combination of conventional pasting therapy and modern preparation technology, the traditional Chinese medical ointment for treating shoulder-hand syndrome provided by the invention is green, low-carbon and environmental-friendly. Kangmo paste which is a novel transdermal drug delivery preparation is prepared to bring good news to massive patients suffering from shoulder-hand syndrome. The preparation is remarkable in curative effect and convenient to use, and does not cause pains to the patients, so that the traditional Chinese medical ointment for treating shoulder-hand syndrome is an innovation of medicines for treating shoulder-hand syndrome.
Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program.
Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
PURPOSE: A composition with antibacterial activity, containing galla rhois extract is provided to ensure excellent antibacterial effect and to use as veterinary medicinary medicinal composition and feed additive. CONSTITUTION: A veterinary medicinal composition for preventing and treating helicobacter bacterial infection contains 0.1-50 weight% of galla rhois extract as an active ingredient. The galla rhois extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. The animal of helicobacter infection is mammals, fishes, and poultry. The helicobacter bacteria are Helicobacter pylori, Helicobacter heilmannii, Helicobacter felis, Helicobacter mustelae, Helicobacter fenelliae, Helicobacter rappini, Helicobacter hepaticus, Helicobacter bilis, or Helicobacter pullorum. An animal feed additive for preventing and treating helicobacter bacteria infection contains galla rhois extract as an active ingredient.
The invention belongs to the field of traditional Chinese medicine, and discloses a pharmaceutical composition for treating pyrophlegm attacking type primary prosopalgia and a preparation method thereof. The pharmaceutical composition is composed of internal medicine and external medicine. The internal medicine is prepared from siegesbeckia pubescens, tubers of serrate sikoku jackinthepulpit, roots of moghania fruticulosa, coptis chinensis, common perilla fruits, pummelo peel, the rhizome of chuanxiong, rhizoma atractylodis macrocephalae, stems and leaves of ficus formosana and liquorice roots. The external medicine is prepared from rhizoma typhonii, mint and garden balsam stem. The internal medicine has the effects of eliminating dampness and phlegm and clearing heat-fire, meanwhile, the Zang-Fu function is conditioned, the water channel is smooth, phlegmatic hygrosis is not generated, and the root causes of pyrophlegm attacking type primary prosopalgia are treated. The medicine is externally used and directly acts on acupoints and main and collateral channels, and achieves the function of fast relieving pain aiming at local vein shrinkage caused by exogenous evils, and the external medicine is used in combination with the internal medicine to further enhance the treatment effect on pyrophlegm attacking type primary prosopalgia.
In controlled clinical trials of acamprosate calcium, adverse events of a suicidal nature (suicidal ideation, suicide attempts, completed suicides) were infrequent overall, but were more common in acamprosate calcium-treated patients than in patients treated with placebo (1.4% vs. 0.5% in studies of 6 months or less; 2.4% vs. 0.8% in year-long studies). Completed suicides occurred in 3 of 2272 (0.13%) patients in the pooled acamprosate group from all controlled studies and 2 of 1962 patients (0.10%) in the placebo group. Adverse events coded as "depression" were reported at similar rates in acamprosate calcium-treated and placebo-treated patients. Although many of these events occurred in the context of alcohol relapse, and the interrelationship between alcohol dependence, depression and suicidality is well-recognized and complex, no consistent pattern of relationship between the clinical course of recovery from alcoholism and the emergence of suicidality was identified. Alcohol-dependent patients, including those patients being treated with acamprosate calcium, should be monitored for the development of symptoms of depression or suicidal thinking. Families and caregivers of patients being treated with acamprosate calcium should be alerted to the need to monitor patients for the emergence of symptoms of depression or suicidality, and to report such symptoms to the patient's health care provider.
AIMS: This work sought to investigate the mechanism underlying the STING signaling pathway during myocardial infarction (MI), and explore the involvement and the role of SIRT6 in the process.
MAIN METHODS: Mice underwent the surgery of permanent left anterior descending (LAD) artery constriction. Primary cardiomyocytes (CMs) and fibroblasts were subjected to hypoxia to mimic MI in vitro. STING expression was assessed in the infarct heart, and the effect of STING inhibition on cardiac fibrosis was explored. This study also evaluated the regulatory effect of STING by SIRT6 in macrophages.
KEY FINDINGS: STING protein was increased in the infarct heart tissue, highlighting its involvement in the post-MI inflammatory response. Hypoxia-induced death of CMs and fibroblasts contributed to the upregulation of STING in macrophages, establishing the involvement of STING in the intercellular signaling during MI. Inhibition of STING resulted in a significant reduction of cardiac fibrosis at day 14 after MI. Additionally, this study identified SIRT6 as a key regulator of STING via influencing its acetylation and ubiquitination in macrophages, providing novel insights into the posttranscriptional modification and expression of STING at the acute phase after myocardial infarction.
SIGNIFICANCE: This work shows the key role of SIRT6/STING signaling in the pathogenesis of cardiac injury after MI, suggesting that targeting this regulatory pathway could be a promising strategy to attenuate cardiac fibrosis after MI.
The invention provides a purpose of baicalin on promoting the directional division in vitro of mesenchymal stem cells in bone marrow. The invention also provides a method of promoting that the mesenchymal stem cells in bone marrow differentiate into liver cells in vitro. The invention adopts baicalin as cell differentiation accelerant; under the condition that fibroblast growth factor-4(FGF-4) exists, the invention induces the mesenchymal stem cells in bone marrow to directionally differentiate into liver cells. The invention also provides a purpose that mesenchymal stem cells in bone marrow in vitro uses the liver cells, which is induced and directionally divided into by baicalin, as the seed cells of liver tissue engineering and cell transplantation, or as the bio-artificial liver. The invention also provides the purpose of baicalin or the baicalin combined with the transplantation of mesenchymal stem cells in bone marrow in preparing liver diseases treating medicine as the cell differentiation accelerant; the baicalin is prepared into the medicine treating liver diseases, the transplantation of mesenchymal stem cells in bone marrow is combined to treat heavy liver disease. The invention also provides the purpose of baicalin containing cell preserving liquid in seed cells storage.
The invention relates to the field of traditional Chinese medicines, and discloses two traditional Chinese medicine formulas for treating depression and anxiety by alternately taking, namely a Huitian prescription and a deficiency-labor prescription. The recipe of returning to the sky warms and supplements the spleen and the kidney, promotes appetite and calms heart spirit; the deficiency-labor formula soothes liver and relieve depression, tonify qi and strengthen kidney, and promote spirit. The prevalence rate of depression and anxiety disorder is high, the harm is large, the recurrence rate is high, and the effective therapeutic drugs with few side effects are lacked. Clinically, most patients suffering from depression and anxiety have symptoms of deficiency besides stagnation of liver and gall pulse, usually the left and right kidney pulse are deep, and the patients are difficult to take care of the whole pathogenesis by using only one prescription. The two traditional Chinese medicine formulas of the project have the effects of soothing liver and relieving depression, and simultaneously replenishing qi to invigorate spleen, tonifying kidney and replenishing essence. The deficiency labor prescription is biased to the left and the heaven prescription is biased to the right, and the two prescriptions are taken alternately every day, so that qi and blood yin and yang on the left and right sides can be balanced and supplemented while soothing liver and relieving depression; not only relieve depression and anxiety symptoms, but also promote appetite and improve qi and blood level of patients, and has little side effect on human bodies.
A method for developing codes and a cross functional set of rules that suggest to a physician, in real-time, potential diagnoses related to diagnostic results or other clinical data entered into the electronic Medical Record (EMR). The method generates a possible diagnosis for consideration and addition to the patient problem list. When the physician selects a suggested diagnosis, the problem list is automatically updated with the diagnosis. In view of the above, the physician has the needed information at the point of care so that the timeliness, safety and quality of care is improved. The generated documentation also assists other physicians throughout the continuum of care for the Patient. The method creates crosswalk from data element to diagnosis to enhance the completeness of documentation. As a result, the Diagnostic Related Group (DRG) is more accurately assigned by coders at discharge to drive more accurate and efficient billing for improved reimbursement and revenue.
Disclosed herein are compositions and methods related to RgIA4 peptide analogs. An RgIA4 peptide analog can comprise a recognition finger region configured to bind to an α9α10 nicotinic acetylcholine receptor. The RgIA4 peptide analog can comprise at least two disulfide bridges comprising: an inter-cysteine disulfide bridge between a first cysteine and a second cysteine, and a penicillamine-cysteine disulfide bridge between a first penicillamine and a third cysteine. The RgIA4 peptide analog can have a binding affinity for the α9α10 nicotinic acetylcholine receptor that is at least 50% of a binding affinity of an RgIA4 peptide. A method of maintaining an RgIA4 peptide potency for an α9α10 nicotinic acetylcholine receptor in an RgIA4 peptide analog can comprise providing a composition as disclosed herein. A method for treating a condition responsive to α9α10 nicotinic acetylcholine receptor binding can comprise administering a therapeutically effective amount of the composition to the subject.
It is unknown if recurrent urinary tract infection in the gynecologic population is associated with Mycoplasma and Ureaplasma genitourinary infections. The purpose of this scoping review is to highlight the literature surrounding Mycoplasma and Ureaplasma infections in the setting of recurrent urinary tract infections in the gynecologic population. MEDLINE ALL and Embase were searched to retrieve articles published in or after 1950 through 2024. Studies included were those with adults over age 18, non-pregnant, diagnosed with recurrent urinary tract infection and concurrent genitourinary infection with Ureaplasma or Mycoplasma published in English. Study designs eligible were quantitative, qualitative, and mixed methods studies. Publication types were also extended to conference abstracts and unpublished data. 2 independent investigators systematically performed title/abstract screening and full-text review using standardized inclusion criteria. For disagreements in either title and abstracts or full-text articles, consensus was reached through discussion by the 2 screeners and/or a 3rd final adjudicator. Screening and data extraction were performed on Covidence, a web-based platform for systematic review management. There were 1170 studies identified before title and abstract screening. 26 full-text articles were reviewed for eligibility. Of these, 23 full-text studies were excluded. 3 studies met full inclusion criteria and data extraction was performed on these 3 studies. There were 2 additional studies included after identification via other methods. There is a need for more recent and robust studies examining the role of Ureaplasma and Mycoplasma genitourinary infections amongst gynecologic patients with recurrent urinary tract infections.
The deep neck flexors are important for maintaining neck posture by stabilizing and supporting it through low-intensity contraction, ensuring static endurance. The subjects performed computer tasks after having their deep neck flexor endurance measured using a pressure biofeedback unit. The craniovertebral angle (CVA) and the muscle activities were measured while participants were completing computer tasks for 10 min. The deep neck flexor endurance was significantly negatively correlated with CVA changes at 0-2 min. The deep neck flexor endurance was significantly negatively correlated with sternocleidomastoid muscle and upper trapezius activity at 0-2 min. The deep neck flexor endurance negatively predicted CVA changes at 0-2 min and explained 28.8% of the variance in the CVA changes. The lower the deep neck flexor endurance, the earlier the simultaneous changes occurred in the CVA and the neck and shoulder muscle activities during computer tasks.